Natural History of Oculo-Pharyngeal Muscular Dystrophy (OPMD) - Israel National OPMD Registry
Launched by SHEBA MEDICAL CENTER ยท
Trial Information
Current as of September 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying Oculopharyngeal Muscular Dystrophy (OPMD), a rare condition that affects the muscles around the eyes and throat. The main goal is to understand how this disease develops and changes over time in people living in Israel. By following patients at different stages of OPMD, the researchers hope to learn more about the natural course of the condition, which can help improve future care and treatments.
The study is open to adults aged 65 to 74 who have been diagnosed with OPMD, regardless of gender. Participants will be observed over time through regular check-ups and assessments, but no experimental treatments are involved. This means they can expect to share information about their symptoms and health in a supportive and careful setting. If you or a family member have OPMD and fit the age range, joining this study could help doctors better understand the condition and contribute to research that may benefit others with OPMD in the future.
Gender
ALL
Eligibility criteria
About Sheba Medical Center
Sheba Medical Center, located in Israel, is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, Sheba Medical Center leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes and developing novel therapeutic interventions. The center's collaborative environment fosters partnerships with global research organizations, enhancing its ability to contribute to the scientific community and drive medical advancements across various fields. With a strong focus on patient safety and ethical standards, Sheba Medical Center is dedicated to translating research findings into practical applications that benefit patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported